search
Back to results

A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) (ATTITUD)

Primary Purpose

Urticaria, Chronic Idiopathic Urticaria

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
desloratadine
desloratadine
Sponsored by
Organon and Co
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urticaria

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
  • Subjects must be >= 18 years of age
  • Women of childbearing potential must have a negative urine pregnancy test at Visit 1 (Day 1) and must be using an acceptable method of birth control during the study.
  • Subjects must be in general good health; ie, they must be free of any clinically significant disease (other than CIU) that would interfere with study evaluations.
  • Subjects must understand and be able to adhere to visit schedules, and agree to complete the questionnaires and a diary.
  • Subjects must have at least a 6-week history of CIU (pruritus and hives) prior to Visit 1.

Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Subjects who used any investigational drug in the last 30 days prior to Visit 1
  • Subjects with asthma requiring chronic use of inhaled or systemic corticosteroids.
  • Subjects who have been treated with any investigational antibodies for asthma or allergic rhinitis in the 90 days prior to Baseline.
  • Subjects who have been treated with intra-muscular or intra-articular corticosteroids in the 90 days prior to Baseline.
  • Subjects with urticaria that is primarily due to physical urticaria or other known etiology, except dermographism.
  • Subjects treated by immunosuppressive drugs.
  • Subjects who have been hospitalized (including an emergency department visit) because of deterioration in their CIU within 3 months prior to Visit 1.
  • Subjects with a history of hypersensitivity to desloratadine or any of its excipients.
  • Subjects previously randomized into this study.
  • Subjects who have any clinically significant metabolic, cardiovascular, immunological, neurological, hematological, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect subject safety.
  • Subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study.
  • Subjects with a history of noncompliance with medications or treatment protocols.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Continuous Treatment

    PRN regimen

    Arm Description

    Outcomes

    Primary Outcome Measures

    Changes from Visit 2 to Visit 4 of Vq-derm questionnaire score and DLQI quality of life score.

    Secondary Outcome Measures

    Estimation of disease free period after 3 months of daily treatment.
    Average usage of rescue medication
    Change from Visit 2 in pruritus symptom score assessed by the patient.
    % of patients free of symptoms 2 months after Visit 4
    Changes from Visit 2 of overall conditions of CIU
    Discontinuation due to treatment failure
    Investigator's assessment of response to therapy
    Quality of disease control
    Average consumption of treatment between Visit 2 and Visit 5

    Full Information

    First Posted
    October 30, 2008
    Last Updated
    February 7, 2022
    Sponsor
    Organon and Co
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00783354
    Brief Title
    A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
    Acronym
    ATTITUD
    Official Title
    A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® "Continuous Treatment" Versus Aerius® "PRN Regimen" on Chronic Idiopathic Urticaria Patient Quality of Life
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    April 1, 2003 (Actual)
    Primary Completion Date
    February 1, 2004 (Actual)
    Study Completion Date
    April 1, 2004 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Organon and Co

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This double-blind pilot study was conducted to establish the best way of using desloratadine treatment to protect quality of life of chronic idiopathic urticaria (CIU) patients, after an initial 4-weeks of daily treatment: prolonging systematic daily treatment or as needed (PRN; in the case of symptoms).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Urticaria, Chronic Idiopathic Urticaria

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    129 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Continuous Treatment
    Arm Type
    Active Comparator
    Arm Title
    PRN regimen
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    desloratadine
    Other Intervention Name(s)
    Aerius, SCH 34117
    Intervention Description
    Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (Placebo) in case of symptoms for 2 months.
    Intervention Type
    Drug
    Intervention Name(s)
    desloratadine
    Other Intervention Name(s)
    Aerius, SCH 34117
    Intervention Description
    Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (desloratadine 5 mg) in case of symptoms for 2 months.
    Primary Outcome Measure Information:
    Title
    Changes from Visit 2 to Visit 4 of Vq-derm questionnaire score and DLQI quality of life score.
    Time Frame
    2 months
    Secondary Outcome Measure Information:
    Title
    Estimation of disease free period after 3 months of daily treatment.
    Time Frame
    2 months
    Title
    Average usage of rescue medication
    Time Frame
    2 months
    Title
    Change from Visit 2 in pruritus symptom score assessed by the patient.
    Time Frame
    2 months
    Title
    % of patients free of symptoms 2 months after Visit 4
    Time Frame
    2 months
    Title
    Changes from Visit 2 of overall conditions of CIU
    Time Frame
    2 months
    Title
    Discontinuation due to treatment failure
    Time Frame
    2 months
    Title
    Investigator's assessment of response to therapy
    Time Frame
    2 months
    Title
    Quality of disease control
    Time Frame
    2 months
    Title
    Average consumption of treatment between Visit 2 and Visit 5
    Time Frame
    4 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent. Subjects must be >= 18 years of age Women of childbearing potential must have a negative urine pregnancy test at Visit 1 (Day 1) and must be using an acceptable method of birth control during the study. Subjects must be in general good health; ie, they must be free of any clinically significant disease (other than CIU) that would interfere with study evaluations. Subjects must understand and be able to adhere to visit schedules, and agree to complete the questionnaires and a diary. Subjects must have at least a 6-week history of CIU (pruritus and hives) prior to Visit 1. Exclusion Criteria: Women who are pregnant or nursing. Subjects who used any investigational drug in the last 30 days prior to Visit 1 Subjects with asthma requiring chronic use of inhaled or systemic corticosteroids. Subjects who have been treated with any investigational antibodies for asthma or allergic rhinitis in the 90 days prior to Baseline. Subjects who have been treated with intra-muscular or intra-articular corticosteroids in the 90 days prior to Baseline. Subjects with urticaria that is primarily due to physical urticaria or other known etiology, except dermographism. Subjects treated by immunosuppressive drugs. Subjects who have been hospitalized (including an emergency department visit) because of deterioration in their CIU within 3 months prior to Visit 1. Subjects with a history of hypersensitivity to desloratadine or any of its excipients. Subjects previously randomized into this study. Subjects who have any clinically significant metabolic, cardiovascular, immunological, neurological, hematological, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect subject safety. Subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study. Subjects with a history of noncompliance with medications or treatment protocols.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    19133920
    Citation
    Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009 Apr;64(4):605-12. doi: 10.1111/j.1398-9995.2008.01913.x. Epub 2008 Dec 30.
    Results Reference
    result
    Available IPD and Supporting Information:
    Available IPD/Information Type
    CSR Synopsis
    Available IPD/Information URL
    http://www.merck.com/clinical-trials/policies-perspectives.html

    Learn more about this trial

    A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)

    We'll reach out to this number within 24 hrs